GlassScriptPhysician profile
Rashmin Adesara
NPI 1699975185
$5,053.11
in general payments reported to CMS, 2019-2025
32 companies · $2,687 in 2025
The $2,687 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $188 · 2021: $250 · 2022: $431 · 2023: $280 · 2024: $366 · 2025: $2,687.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,833 · Consulting Fee: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.48 |
| Consulting Fee | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,619.83 | 2019-2025 | Collagenase Santyl, Regranex, Pico |
| Novo Nordisk INC | $418.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Integra Lifesciences Corporation | $409.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $377.81 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $357.69 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $311.09 | 2023-2025 | |
| Pfizer INC. | $202.04 | 2019-2025 | |
| Lilly USA, LLC | $186.07 | 2022-2025 | Mounjaro, Zepbound, Kisunla |
| Bioventus LLC | $171.48 | 2022 | |
| Amgen INC. | $141.80 | 2019 | |
| Organogenesis INC. | $123.74 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.78 | 2025 | Caplyta |
| Abbott Laboratories | $77.51 | 2022-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $73.94 | 2023-2024 | |
| Astellas Pharma US INC | $61.40 | 2019-2025 | Veozah |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $46.04 | 2022-2025 | |
| Exact Sciences Corporation | $43.95 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $34.86 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Eisai INC. | $34.71 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $34.04 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $23.54 | 2025 | Jornay Pm |
| Regeneron Healthcare Solutions, INC. | $22.31 | 2024 | Evkeeza |
| Allergan, INC. | $21.67 | 2019 | |
| Dexcom, INC. | $21.07 | 2025 | Dexcom G6 Transmitter |
| Alnylam Pharmaceuticals INC. | $20.90 | 2024 | Onpattro |
| Seqirus USA INC | $20.21 | 2025 | Flucelvax, Fluad |
| Rgh Enterprises LLC | $16.31 | 2025 | |
| Cranial Technologies, INC | $15.76 | 2024 | Doc Band |
| Sanofi-Aventis U.S. LLC | $15.03 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.89 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $13.52 | 2023 | Eliquis |
| Misonix INC | $12.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmin Adesara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.